Back to News
Market Impact: 0.2
Capricor Therapeutics Average Analyst Price Target Rises 12.70% to $24.14
Source: Nasdaq
Analyst EstimatesAnalyst InsightsHealthcare & Biotech
Capricor Therapeutics' average 12-month analyst price target was raised 12.7% to $24.14 per share from $21.42 on September 11, 2026. The revision indicates improved analyst expectations for the biotech company, though the article provides no underlying earnings, clinical, or operational catalyst.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
CAPR0.45
More News
- Your health insurance premiums may take a big jump in 2027 — here's why
- Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals
- Tesla reports 486,532 vehicle deliveries for third quarter, topping expectation
- Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
- Why AMD Stock Jumped 30% in September
- Nike falls to 13-year low. Why analysts don't think the selling is over yet